August 2012
-
US grocer Albertsons will begin selling Lupin’s InspiraChamber antistatic valved holding chamber exclusively in more than 1,700 pharmacies in 35 US states, Lupin has announced. The InspiraChamber spacer can be used with one of several… Read more . . .
-
MannKind Corporation has announced the appointment of Michael Castagna as Chief Executive Officer, effective May 25, 2017. Castagna takes over the role from Matthew Pfeffer, who succeeded Alfred Mann as CEO in January 2016. Pfeffer… Read more . . .
-
According to Sunovion, the FDA has issued a complete response letter (CRL) for its NDA for SUN-101/eFlow glycopyrrolate inhalation solution for the treatment of COPD. Sunovion submitted the NDA for SUN-101/eFlow in July 2016, and… Read more . . .
-
Elran Haber, CEO of Therapix Biosciences, which is developing intranasal cannabinoid-based drugs, will step down “to pursue other professional opportunities” after the company concludes its search for “a permanent, US based Chief Executive Officer,” the… Read more . . .
-
Horizon Pharma has agreed to sell Raptor Pharmaceuticals, which owns the rights to Quinsair levofloxacin inhalation solution in Europe, the Middle East and Africa, to Chiesi Farmaceutici for $70 million and potential sales-based milestone payments,… Read more . . .
-
Generic device company Merxin has announced the launch of its MRX003 dry powder inhaler, an off-the-shelf capsule based DPI intended for generic tiotropium 505j submissions. According to an announcement by Merxin’s sister company Aedestra, the… Read more . . .
-
Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal… Read more . . .
-
Vectura has announced that it is presenting positive results from a Phase I clinical study of VR942, an inhaled anti-IL-13 monoclonal fragment antibody, at the American Thoracic Society 2017 International Conference. Vectura is partnered with… Read more . . .
-
Chiesi Group has announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding the company’s MAA for Trimbow beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide MDI. Chiesi has applied to… Read more . . .
-
Submit abstracts by 28 July 2017 at https://aerosol-soc.com/abstract-submission/ Themes for DDL 2017 are Inhaled Therapy in Special Populations, Emerging Therapeutics and Novel Respiratory Medicines, Inhalation Devices and Aerosol Science, and Modelling and Simulations in Inhalation… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.